deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT06564753

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition

Sponsor: Biomed Industries, Inc.

Conditions Body Weight Body Weight Changes Obesity Weight Loss
Interventions Drug: Placebo daily and orally NA-931 dose 3, daily and orally NA-931 dose 4, daily and orally NA-931, dose 1, daily and orally NA-931, dose2, daily and orally
Updated 3 times since 2024 Last updated: May 20, 2025 Started: Jul 19, 2024 Primary completion: Feb 27, 2025 Completion: Apr 18, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Body Weight and Body Weight Changes and is currently completed. Biomed Industries, Inc. leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotRecruiting~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

3 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  3. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biomed Industries, Inc.
Data source: Biomed Industries, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations